BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Dipsacus Asper

100+ PubMed studies analyzed · 1 RCTs · Evidence Score: 30.8

Research Domains

Dipsacus Asper has been studied across 23 research domains including 🔬 Oncology, 🔬 Inflammation, 🦴 Bone & Joint, 🧘 Stress & Anxiety, ❤️ Cardiovascular. The primary research focus is 🔬 Oncology with 18% of studies addressing this area.

Traditional Use (Ayurveda)

Known as xuduan / 續斷 in Ayurveda. Virya (potency): Kidney, Liver. Rasa (taste): Bitter, Pungent. Karma (actions): Supplements insufficiency, Heals metal-wound sores, Treats carbuncles and ulcerations, Reconnects sinews and bones after fractures and falls, Benefits Qi and strength, Stops bleeding and pain, Generates flesh, Removes all warm toxins, Promotes and disseminates Blood vessels, Assists Qi, Breaks up concretion-masses and stasis Blood, Disperses swelling toxin, Contracts the urine, Stops seminal emission and urinary Blood.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Dipsacus Asper, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

citrus
62 shared targets
typha
52 shared targets
chrysanthemum
60 shared targets
gentiana
53 shared targets
daemonorops
41 shared targets
astragalus
35 shared targets
boswellia
29 shared targets
plantago
22 shared targets
angelica
20 shared targets
coptis
15 shared targets
Loading evidence profile...

This evidence profile for Dipsacus Asper is generated deterministically from 100 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.